A pharmaceutical composition comprising risedronate and vitamin D is provided to minimize side effects of the risedronate, deliver the vitamin D into the mucosa of small intestine effectively and improve the stability of the vitamin D by blocking the interaction between the vitamin D and the risedronate. A pharmaceutical composition for treating metabolic bone diseases comprises: a risedronate tablet including 1 part by weight of risedronate and a pharmaceutically acceptable excipient; a release-delay coating layer prepared by coating 0.01-0.3 part by weight of an enteric coating polymer on the risedronate tablet; and a vitamin D isolation coating layer prepared by coating 0.1-0.3 part by weight of a water-soluble polymer and 0.0001-0.01 part by weight of a vitamin D compound on the release-delay coating layer, wherein the enteric coating polymer is selected from the group consisting of a copolymer of methacrylic acid and acrylate, hydroxypropyl cellulose phthalate and cellulose acetate phthalate. Further, the water-soluble polymer is selected from hydroxypropylmethylcellulose, polyvinylpyrrolidone or poly vinyl alcohol.
展开▼
